United Therapeutics Shares Outstanding 2006-2018 | UTHR

United Therapeutics shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • United Therapeutics shares outstanding for the quarter ending September 30, 2018 were 0.044B, a 0.23% decline year-over-year.
  • United Therapeutics 2017 shares outstanding were 0.045B, a 4.06% decline from 2016.
  • United Therapeutics 2016 shares outstanding were 0.047B, a 8.59% decline from 2015.
  • United Therapeutics 2015 shares outstanding were 0.051B, a 5.54% decline from 2014.
United Therapeutics Annual Shares Outstanding
(Millions of Shares)
2017 45
2016 47
2015 51
2014 54
2013 53
2012 53
2011 59
2010 60
2009 56
2008 46
2007 45
2006 48
2005 50
United Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 44
Q2 2018 43
Q1 2018 44
Q4 2017 45
Q3 2017 44
Q2 2017 45
Q1 2017 46
Q4 2016 47
Q3 2016 46
Q2 2016 47
Q1 2016 49
Q4 2015 51
Q3 2015 50
Q2 2015 52
Q1 2015 47
Q4 2014 54
Q3 2014 47
Q2 2014 53
Q1 2014 57
Q4 2013 53
Q3 2013 54
Q2 2013 53
Q1 2013 52
Q4 2012 53
Q3 2012 54
Q2 2012 54
Q1 2012 55
Q4 2011 59
Q3 2011 61
Q2 2011 63
Q1 2011 63
Q4 2010 60
Q3 2010 60
Q2 2010 60
Q1 2010 60
Q4 2009 56
Q3 2009 58
Q2 2009 53
Q1 2009 54
Q4 2008 46
Q3 2008 51
Q2 2008 49
Q1 2008 48
Q4 2007 45
Q3 2007 45
Q2 2007 44
Q1 2007 43
Q4 2006 48
Q3 2006 50
Q2 2006 51
Q1 2006 51
Q4 2005 50
Q3 2005 51
Q2 2005 50
Q1 2005 49
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $5.045B $1.725B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $40.641B 27.83
Takeda Pharmaceutical (TAK) Japan $30.903B 14.44
Grifols (GRFS) Spain $13.311B 16.13
Neurocrine Biosciences (NBIX) United States $8.300B 1830.60
Nektar Therapeutics (NKTR) United States $7.997B 11.46
Ionis Pharmaceuticals (IONS) United States $7.983B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.786B 11.18
Tilray (TLRY) United States $7.192B 0.00
Loxo Oncology (LOXO) United States $7.148B 0.00
Sage Therapeutics (SAGE) United States $6.554B 0.00
Catalent (CTLT) United States $5.177B 21.71
FibroGen (FGEN) United States $4.480B 0.00
TESARO (TSRO) United States $4.126B 0.00
Impax Laboratories (AMRX) United States $3.708B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.700B 13.70
USANA Health Sciences (USNA) United States $2.852B 24.28
Endo (ENDP) Ireland $2.176B 3.33
Heron Therapeutics (HRTX) United States $2.109B 0.00
Aerie Pharmaceuticals (AERI) United States $2.000B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.989B 0.00
Xencor (XNCR) United States $1.892B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.848B 0.00
Zogenix (ZGNX) United States $1.811B 0.00
Portola Pharmaceuticals (PTLA) United States $1.762B 0.00
PTC Therapeutics (PTCT) United States $1.738B 0.00
Corcept Therapeutics (CORT) United States $1.725B 25.32
Pacira Pharmaceuticals (PCRX) United States $1.646B 222.44
Theravance Biopharma (TBPH) Cayman Islands $1.508B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.494B 21.01
Arrowhead Pharmaceuticals (ARWR) United States $1.339B 0.00
TherapeuticsMD (TXMD) United States $1.216B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.166B 0.00
Esperion Therapeutics (ESPR) United States $1.154B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.030B 0.00
Tricida (TCDA) United States $0.925B 0.00
Radius Health (RDUS) United States $0.797B 0.00
ImmunoGen (IMGN) United States $0.760B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.644B 0.00
ChemoCentryx (CCXI) United States $0.629B 49.80
Karyopharm Therapeutics (KPTI) United States $0.599B 0.00
Siga Technologies (SIGA) United States $0.590B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.553B 0.00
Flexion Therapeutics (FLXN) United States $0.552B 0.00
Collegium Pharmaceutical (COLL) United States $0.524B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.484B 28.55
GlycoMimetics (GLYC) United States $0.466B 0.00
Odonate Therapeutics (ODT) United States $0.457B 0.00
Forty Seven (FTSV) United States $0.450B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.431B 0.00
Aptorum Group (APM) China $0.418B 0.00
ArQule (ARQL) United States $0.408B 0.00
Akebia Therapeutics (AKBA) United States $0.365B 0.00
Majesco Entertainment (PTE) United States $0.358B 0.00
Xeris Pharmaceuticals (XERS) United States $0.355B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.348B 0.00
CASI Pharmaceuticals (CASI) United States $0.347B 0.00
Concert Pharmaceuticals (CNCE) United States $0.333B 0.00
Lannett Co Inc (LCI) United States $0.300B 2.60
OptiNose (OPTN) United States $0.296B 0.00
KalVista Pharmaceuticals (KALV) United States $0.288B 0.00
Dermira (DERM) United States $0.286B 0.00
Minerva Neurosciences (NERV) United States $0.275B 0.00
Tapimmune (MRKR) United States $0.272B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.269B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.268B 0.00
Depomed (ASRT) United States $0.267B 9.95
IMV INC (IMV) Canada $0.264B 0.00
Aclaris Therapeutics (ACRS) United States $0.260B 0.00
Mast Therapeutics (SVRA) United States $0.259B 0.00
Translate Bio (TBIO) United States $0.250B 0.00
Tyme Technologies (TYME) United States $0.249B 0.00
Opexa Therapeutics (ACER) United States $0.243B 0.00
Aldeyra Therapeutics (ALDX) United States $0.234B 0.00
Dova Pharmaceuticals (DOVA) United States $0.232B 0.00
TAIWAN LIPOSOME (TLC) Taiwan $0.230B 0.00
Affimed (AFMD) Germany $0.221B 0.00
Aratana Therapeutics (PETX) United States $0.215B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.201B 0.00
Galectin Therapeutics (GALT) United States $0.195B 0.00
MEI Pharma (MEIP) United States $0.194B 0.00
Zafgen (ZFGN) United States $0.175B 0.00
Aquestive Therapeutics (AQST) United States $0.173B 0.00
Recro Pharma (REPH) United States $0.172B 0.00
Calithera Biosciences (CALA) United States $0.170B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.165B 0.00
Ocular Therapeutix (OCUL) United States $0.163B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.155B 0.00
Molecular Templates (MTEM) United States $0.155B 0.00
Nature's Sunshine Products (NATR) United States $0.154B 0.00
ElectroCore (ECOR) United States $0.148B 0.00
Redhill Biopharma (RDHL) Israel $0.147B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.147B 0.00
Adherex Technologies (FENC) United States $0.139B 0.00
Ardelyx (ARDX) United States $0.139B 0.00
Neon Therapeutics (NTGN) United States $0.138B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.136B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.131B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.130B 0.00
Jounce Therapeutics (JNCE) United States $0.124B 0.00
MediWound (MDWD) Israel $0.118B 0.00
Cardiome Pharma (CORV) Canada $0.115B 0.00
Champions Oncology (CSBR) United States $0.115B 0.00
ProNAi Therapeutics (SRRA) Canada $0.108B 0.00
CHINA SXT PHARM (SXTC) China $0.106B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.094B 0.00
DURECT (DRRX) United States $0.094B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.091B 0.00
Iterum Therapeutics (ITRM) Ireland $0.083B 0.00
Natural Alternatives (NAII) United States $0.083B 8.18
Nivalis Therapeutics (ALPN) United States $0.079B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.074B 0.00
CTI BioPharma (CTIC) United States $0.071B 0.00
Infinity Pharmaceuticals (INFI) United States $0.071B 0.00
Avenue Therapeutics (ATXI) United States $0.070B 0.00
KemPharm (KMPH) United States $0.070B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.069B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.069B 0.00
Immune Design (IMDZ) United States $0.068B 0.00
Otonomy (OTIC) United States $0.062B 0.00
BioLineRx (BLRX) Israel $0.062B 0.00
Neos Therapeutics (NEOS) United States $0.061B 0.00
Achaogen (AKAO) United States $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.058B 0.00
Melinta Therapeutics (MLNT) United States $0.057B 0.00
Genocea Biosciences (GNCA) United States $0.051B 0.00
Forward Pharma (FWP) Denmark $0.050B 0.00
Mannatechorporated (MTEX) United States $0.046B 0.00
ContraFect (CFRX) United States $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
Capnia (SLNO) United States $0.036B 0.00
NOVAN INC (NOVN) United States $0.036B 0.00
Lipocine (LPCN) United States $0.036B 0.00
SCYNEXIS (SCYX) United States $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Heat Biologics (HTBX) United States $0.032B 0.00
PharmAthene (ALT) United States $0.025B 0.00
ESSA Pharma (EPIX) Canada $0.025B 0.00
Trillium Therapeutics (TRIL) Canada $0.025B 0.00
Biomerica (BMRA) United States $0.022B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.022B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.021B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.020B 0.00
Citius Pharmaceuticals (CTXR) United States $0.020B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.020B 0.00
Pain Therapeutics (PTIE) United States $0.019B 0.00
Xenetic Biosciences (XBIO) United States $0.019B 0.00
HANCOCK JAFFE (HJLI) United States $0.019B 0.00
Cyanotech (CYAN) United States $0.018B 0.00
Jaguar Animal Health (JAGX) United States $0.018B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.016B 0.00
Aviragen Therapeutics (VXRT) United States $0.014B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.014B 0.00
Skyline Medical (AIPT) United States $0.013B 0.00
Shineco (TYHT) China $0.012B 1.27
Onconova Therapeutics (ONTX) United States $0.011B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.009B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.007B 0.00
Apricus Biosciences (APRI) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Intellipharmaceutics (IPCI) Canada $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Bio Blast Pharma (ORPN) Israel $0.003B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.001B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00